Our areas of partnering interest

No matter where in the world you may be located, we are interested in exploring leading-edge collaboration opportunities with you – across our main therapy areas and beyond. We carefully consider local medical circumstances and adopt a flexible approach that enables us to meet specific patient needs in key markets.

In China, for example, we are exploring opportunities that support and enhance our existing commercial strength. Our focus is on partnering opportunities from R&D through commercial launch stage, in areas such as paediatric, nebulised, pulmonary, gastric, cardiovascular, and traditional Chinese medicine.

In Japan, we are looking to collaborate with a range of experts to help transform medical practice and patients’ lives. We focus on opportunities at or near commercial launch stage in the areas of oncology; cardiovascular, renal and metabolism; and respiratory and immunology.

Our interest goes beyond pharmaceutical products to diagnostics, devices, and digital technologies. We aim to work with a range of partners to build end-to-end patient solutions that help improve disease awareness, diagnosis, treatment and post-treatment care. While these partnerships are designed to meet the unmet medical needs of local patients, some also have potential to benefit patients globally.

Using our presence and reach, we can also help you commercialise your product in China, Japan and other international markets. Together with the China International Capital Corporation (CICC), we established the AstraZeneca-CICC Healthcare Investment Fund, a private equity fund that promotes the development of medical and healthcare innovation in China by investing in fields such as medicine and biotechnology, diagnostics, medical devices and digital health.